TY  - JOUR
AU  - Sanchez-Gastaldo, Amparo
AU  - Muñoz-Fuentes, Miguel A
AU  - Molina-Pinelo, Sonia
AU  - Alonso-Garcia, Miriam
AU  - Boyero, Laura
AU  - Bernabe-Caro, Reyes
PY  - 2021
DO  - 10.21037/tlcr-21-156
SN  - 2218-6751
UR  - http://hdl.handle.net/10668/18235
T2  - Translational lung cancer research
AB  - Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes and three...
LA  - en
PB  - AME Publishing Company
KW  - Pembrolizumab
KW  - blood biomarkers
KW  - non-small cell lung cancer (NSCLC)
KW  - Neutrophils
KW  - Monocytes
KW  - B7-H1 Antigen
KW  - Progression-Free Survival
KW  - Confidence Intervals
KW  - Lymphocytes
KW  - Leukocyte Count
KW  - Biomarkers
KW  - Multivariate Analysis
KW  - Hospitals
TI  - Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
TY  - research article
VL  - 10
ER  -